Epigenomics confident of achieving FY05 guidance despite Q3 revenue loss
This article was originally published in Clinica
In spite of its success at costs control, German molecular diagnostics company Epigenomics saw its third-quarter 2005 top-line fall 28% to Euro2.1m ($2.5m) from last year's level. The firm also widened its net loss for the period by 6% to Euro2.8m.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.